GSK starts combination trial for melanoma
May 30, 2012Research and Development, Sales and Marketing GSK, R&D, Roche, Zelboraf, melanoma
GlaxoSmithKline has begun a combination trial for two of its investigational skin cancer drugs. The firm will combine dabrafenib, its …
UK Prix Galien shortlist announced
May 30, 2012Business Services, Medical Communications, Research and Development, Sales and Marketing Bayer, Janssen, Xarelto, awards, prix galien
The UK award for the most innovative new drug has been moved a step closer with the release of a …
Onyx appoints Brian Jolly to commercial team
May 30, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing CMO, Onyx, manufacturing
Onyx Scientific the chemistry and manufacturing specialist has bolstered its business development team with the appointment of a new director. …
Landmark CF treatment set for European approval
May 30, 2012Sales and Marketing CHMP, Europe, Kalydeco, Vertex, cystic fibrosis
A European committee is recommending the approval of Vertex’s first-in-class treatment for cystic fibrosis. Kalydeco (ivacaftor) is a landmark in …
Government outlines new commissioning landscape
May 29, 2012CCG, NHS, PCTs, commissioning, health reforms
The government has outlined the new commissioning landscape in England as GPs look to take over commissioning responsibility. The NHS …
Sanofi/Regeneron cholesterol drug reaches Phase III
May 29, 2012Research and Development, Sales and Marketing Amgen, PCKS9, Regeneron, SAR236553, Sanofi
Sanofi and Regeneron’s anti-cholesterol drug has impressed in a mid-stage trial, and will now progress into Phase III. The firms’ …
Lundbeck’s Alzheimer’s drug shows promise
May 29, 2012Research and Development, Sales and Marketing Alzheimer's, Lundbeck
Lundbeck’s Alzheimer’s candidate Lu AE58054 has shown signs in a phase II study of helping patients’ mental activity. Sufferers receiving …
Pharma manufacturing news in brief
May 29, 2012Manufacturing and Production Adienne Pharma & Biotech, Hospira, Neuroptis Biotech, Provence Technologies, Selexis and Florida Biologix, baxter
Hospira overfilled Carpuject cartridges, high-potency certification at Baxter, plus updates from Provence Technologies, Selexis and Florida Biologix.
EMA backs MabThera despite contamination issue
May 29, 2012Manufacturing and Production EMA, MabThera, Phil Taylor, Roche, manufacturing
The European Medicines Agency has completed a safety review of Roche’s MabThera convened after bacterial contamination was discovered in bioreactors …
Merck extends biocatalysis collaboration with Codexis
May 29, 2012Manufacturing and Production Codexis, Merck, Phil Taylor, Victrelis, manufacturing
Biocatalyst specialist Codexis has signed a three-year extension of its catalyst and process development collaboration with Merck to develop enzymes …
European OK for Pradaxa, but more details required
May 29, 2012Research and Development, Sales and Marketing Boehringer, CHMP, EMA, Europe, Pradaxa
The European Medicines Agency says that Boehringher’s Pradaxa can stay on the market, but will need more safety information. The …
Cancer Drugs Fund ‘the wrong choice’ for Wales
May 29, 2012Sales and Marketing CDF, Cancer, NHS, Wales, Welsh
The Welsh health minister Lesley Griffiths has said that a Cancer Drugs Fund is ‘not the right course’ for Wales. …
Recommendations for two Eisai epilepsy drugs
May 28, 2012Sales and Marketing CHMP, Eisai, Zonegra, epilepsy
European regulators are likely to approve two of Eisai’s epilepsy drugs after advisers recommended both of them.First-in-class Fycompa (perampanel) has …
Latest FDA warning letters cite Tedec-Meiji, BMP Pharma
May 28, 2012Manufacturing and Production BMP Pharma, FDA, Tedec-Meiji Farma
Spanish drugmaker Tedec-Meiji Farma and German active pharmaceutical ingredient (API) producer BMP Pharma both feature in the latest crop of …
Life bolsters its client services team with two additions
May 28, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Life Healthcare Communications has developed its client services team with two new appointments to further support the needs of its …
Pfizer’s Inlyta gains European recommendation
May 28, 2012Sales and Marketing Inlyta. axitinib, Sutent, renal cell carcinoma
Pfizer’s kidney cancer pill Inlyta has been recommended for use by a European committee. The Committee for Medicinal Products for …
Public-private alliance to discover new antibiotics
May 25, 2012AstraZeneca, EFPIA, GSK, Janssen, Sanofi, antibiotic, bacterial infection
A Europe-wide public-private partnership is to put €224m (£180m) into finding new antibiotics for all manner of bacterial infections such …
Groundbreaking CF drug recommended in Europe
May 25, 2012Sales and Marketing CHMP, EMA, Kalydeco, Vertex, cystic fibrosis
The first-in-class treatment for cystic fibrosis Kalydeco has been recommended by the EMA’s medicines committee. Kalydeco (ivacaftor) promises to be …
CHASE announces two appointments
May 24, 2012Business Services, Medical Communications, Sales and Marketing CHASE, MSI
Contract sales organisation CHASE has announced two appointments to its senior management team. A provider of contract and permanent staff …
Pfizer appoints two senior roles
May 24, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Pfizer, Read
Pfizer has named Olivier Brandicourt as president and general manager of its Emerging Markets and Established Products Business Units, and …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
